

From ACT Targets to Technology: Advancing Heparin Monitoring in the Cardiovascular Operating Room

Our speakers will discuss the importance of activated clotting time (ACT) monitoring for unfractionated heparin management, review evidence informing ACT targets in cardiac surgery, and explore how integrated data management can support efficient perioperative workflows.

Date

September 10, 2026

Time

17:00–19:00 CEST

Speakers



Linda Shore-Lesserson, MD, FAHA, FASE

Professor of Anesthesiology
Zucker School of Medicine at Hofstra/Northwell
New York, NY, US



Karin A. M. Gorter, MSc, EKP

Clinical Perfusionist
Heartbeat Dutch Perfusion Service
University Medical Centre, Utrecht
Utrecht, the Netherlands



David Mast, CCP

Manager of Perfusion Services
The Ohio State University
Wexner Medical Center
Richard M. Ross Heart Hospital
Columbus, OH, US

REGISTER NOW



Scan QR code
to register

Following the workshop, Werfen representatives will be available online to answer questions.

Objectives

- Understand the role of ACT monitoring for unfractionated heparin management and the factors contributing to variability among ACT methods
- Review evidence comparing ACT targets for cardiac surgery and associated clinical outcomes*
- Discuss the role of digital connectivity in supporting cardiac surgery workflow efficiency and ACT data management

* This event contains Scientific Information on Unapproved Uses (SIUU) about ACT Targets for the Hemochron product line. These uses have not been cleared by the US FDA and the safety and effectiveness of these claims for the Hemochron product line have not been established.

werfen.com

©2026 Instrumentation Laboratory. All rights reserved.

werfen